Economic evaluation of dorzolamide vs. pilocarpine for primary open-angle glaucoma.
Rocchi
A
A
Axia Research, Hamilton, Ont.
Tingey
D
D
D000287:Administration, Topical; D000368:Aged; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D018803:Models, Economic; D018721:Muscarinic Agonists / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D010862:Pilocarpine / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D013876:Thiophenes / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use
D002257:Carbonic Anhydrase Inhibitors; D018721:Muscarinic Agonists; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; D010862:Pilocarpine; C062765:dorzolamide